oc-000459
Small moleculeexperimental
Clinical trial activity
12 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00290381)
Timeline
Indications
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
- G-protein coupled receptorINHIBITOR
PTGDR2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O- Mol. weight
- 348.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL560993 ↗
Also known as
- (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid
- oc000459
- oc000459
- oc000459
- oc000459
- oc-000459
- oc-000459
- oc459
- oc459
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02560610 | Phase 2 | Sep 1, 2016 | Atopix Therapeutics, Ltd., University of Oxford |
| NCT02660489 | Phase 2 | Oct 1, 2015 | Atopix Therapeutics, Ltd., Medical Research Council, University of London |
| NCT02341521 | Phase 1 | Mar 1, 2015 | Atopix Therapeutics, Ltd., Simbec-Orion |
| NCT02002208 | Phase 2 | Oct 1, 2013 | Atopix Therapeutics, Ltd., Sheffield Hallam University |
| NCT01056783 | Phase 2 | Aug 1, 2010 | Oxagen Ltd, Swiss EoE Research Group |
| NCT01056575 | Phase 1 | Feb 1, 2010 | Oxagen Ltd, Simbec-Orion |
| NCT00890877 | Phase 2 | Apr 1, 2009 | Oxagen Ltd |
| NCT00697281 | Phase 2 | May 1, 2008 | Medical University of Vienna, Oxagen Ltd |
| NCT01448902 | Phase 2 | Mar 1, 2007 | Medical University of Vienna, Oxagen Ltd |
| NCT01057927 | Phase 2 | Jan 1, 2007 | Oxagen Ltd |
| NCT00290381 | Phase 1 | Feb 1, 2006 | National Heart, Lung, and Blood Institute (NHLBI), Oxagen Ltd, University of London |
| NCT01056692 | Phase 2 | Feb 1, 2006 | Oxagen Ltd, University of London, University of Manchester |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oxagen Ltd | For profit | 8 | 7 | 2 | 2006 |
| Atopix Therapeutics, Ltd. | For profit | 4 | 3 | 2 | 2013 |
| University of London | Academic/Hospital | 3 | 2 | 2 | 2006 |
| Medical University of Vienna | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Simbec-Orion | For profit | 2 | 0 | 1 | 2010 |
| Medical Research Council | Government | 1 | 0 | 1 | 2015 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2006 |
| Sheffield Hallam University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Swiss EoE Research Group | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2016 |
11 organizations
Page 1 / 1